

PAN MERSEY AREA PRESCRIBING COMMITTEE MEETING

Minutes of the Meeting held on Wednesday 28th May 2014 in The Gallery Room, at The Venue, Civic Way, off Poplar Bank, Huyton L36 9GD

Present:

MEMBERS		Present	Apologies
Graham Pimblett- Acting Chair	Medicines Management Team Leader – Knowsley CCG	x	
Dr M G Semple	Senior Lecturer in Child Health – Alder Hey Children's NHS Foundation Trust		x
Isam Badhawi	Senior Pharmacist – Liverpool Women's NHS Foundation Trust		x
Catrin Barker	Chief Pharmacist – Alder Hey Children's NHS Foundation Trust		x
Deborah Walker	Alder Hey Children's NHS Foundation Trust (representing Catrin Barker)	x	
Dr Rob Barnett	LMC Representative, Liverpool		x
Nicola Baxter	Head of Medicines Optimisation – West Lancs CCG		x
Janet Walsh	West Lancs (representing Nicola Baxter)	x	
Alison Butt	Joint Head of Medicines Management - Liverpool Community Health		x
Dr Catherine Doyle	Clinical Lead Medicines Management – Warrington CCG	x	
Dr Michael Ejuoneatse	Clinical Lead for Medicines – St Helens CCG		x
Dr Janice Eldridge	GP Medicines Management Lead – Southport & Formby CCG	x	
Alison Ewing	Clinical Director Pharmacy – The Royal Liverpool & Broadgreen University Hospitals NHS Trust		x
Dr Anna Ferguson	GP Clinical Lead – South Sefton CCG		x
Dr Claire Forde	CCG Governing Body Member, Prescribing Lead – Halton CCG		x
Simon Gelder	Chief Pharmacist – St Helens & Knowsley Teaching Hospitals NHS Trust	x	
Margaret Geoghegan	Head of Medicines Management – St Helens CCG	x	
Donna Gillespie-Greene	Deputy Head of Meds Management – Cheshire and Merseyside Commissioning Support Unit	x	
Gillian Gow	Chief Pharmacist – Liverpool Heart & Chest Hospital NHS Foundation Trust		x
Maureen Hendry	Practice pharmacist/Interface support pharmacist, Liverpool Community Health (representing Alison Butt)		x
Dr Aftab Hossain	Clinical Lead, Prescribing – Knowsley CCG		
Peter Johnstone	Prescribing Commissioner – Liverpool CCG		x
Jenny Jones	Principal Pharmacist Medicines Management – Warrington & Halton Hospitals NHS Foundation Trust (representing Diane Matthew)	x	
Dr Cecilia Jukka	Consultant Microbiologist/Chair Drug & Therapeutics Committee – Southport & Ormskirk NHS Trust		x
Lee Knowles	Chief Pharmacist – MerseyCare NHS Trust		x
Jenny Lunn	Pharmaceutical Adviser & Team Lead, Medicines Management – Warrington CCG		x
Janeth Ward	Prescribing Adviser, Medicines Management Team - Warrington CCG	x	

Jen Matthewman	Pharmacist – Bridgewater Community Trust (representing Heather Tomlinson)	x	
Dr Sid McNulty	Consultant Endocrinologist/Chair Drug & Therapeutics Committee – St Helens & Knowsley Teaching Hospitals NHS Trust	x	
Sarah McParland	Pharmacist – KIPPS (representing Neil Chilton, 5 Boroughs Partnership NHS Trust)		
Dr Neil Mercer	Consultant Anaesthetist/Chair Drug & Therapeutics Committee – Aintree Univ Hospitals NHS Trust	x	
Brendan Prescott	CCG Lead Medicines Management – South Sefton CCG and Southport & Formby CCG		x
Lucy Reid	Lead Pharmacist – Halton CCG Locality Medicines Management Team	x	
Dr Shamim Rose	GP Prescribing Lead & Board Sponsor – Liverpool CCG,	x	
Steve Simpson	Deputy Chief Pharmacist – Southport and Ormskirk NHS Trust	x	
Paul Skipper	Deputy Director of Pharmacy – The Royal Liverpool & Broadgreen University Hospitals NHS Trust (representing Alison Ewing)	x	
Dave Thornton	Principal Pharmacist, Clinical Services – Aintree University Hospitals NHS Trust (representing Mags Norval)	x	
Heather Tomlinson	Senior Clinical Pharmacist – Bridgewater Community Trust	x	
Janet Fay	Senior Pharmacist, – South Sefton CCG and Southport & Formby CCG	x	
IN ATTENDANCE			
Erika Baker	Senior Pharmacist – Cheshire & Merseyside CSU	x	
Anne Henshaw	Senior Pharmacist – Cheshire & Merseyside CSU	x	
Clare Moss	Senior Pharmacist – Cheshire & Merseyside CSU	x	
Graham Reader	Senior Pharmacist – Cheshire & Merseyside CSU	x	
Helen Stubbs	Senior Pharmacist – Cheshire & Merseyside CSU	x	

1	APC/14/38 – Welcome and Apologies for Absence The Chair welcomed the members and accepted the apologies of the following: Catrin Barker (Debra Walker attending), Gillian Gow, Anna Ferguson, Jenny Lunn (Jan Ward attending), Dr Tom Kennedy, Dr Michael Ejuoneatse, Alison Ewing (Paul Skipper attending), Alison Butt, Brendan Prescott (Janet Fay attending), Dr Claire Forde	Action:
2	APC/14/39 – Declarations of Interest and Quoracy Check A quoracy check informed that there were 2 hospital clinicians and 3 GPs present meaning the meeting was not quorate. There were no declarations of interest at this meeting.	
3	APC/14/40 – Minutes of the previous meeting and matters arising. 14/40/01 – Minutes from the Previous Meeting The Chair highlighted an issue with the wording on item 14/36/02 – “There was no enthusiasm for this”. It was agreed that the wording would be changed to “the matter was discussed and the consensus was that this would not be necessary.” The Chair asked if there were any updates regarding item 14/32/07 (Anti-epileptic generic switching update) and was informed that there had been none. With regards to item 14/31/01 (Grey Statement Summary), the chair highlighted the amount of advertising (by pharmaceutical companies) and patients had been asking for Mirvaso [®] ▼ and Vesomni [®] .	AH/DGG

	<p>Matters Arising: 14/40/02 – Iluvien® The committee was informed that all CCGs had approved NICE TA for Iluvien® within the 90 day timescale required by NICE. It had been suggested at a previous meeting that Sefton CCG had not achieved the deadline, however, this was not the case.</p>	DGG
4	<p>APC/14/41 – New Medicines 14/41/01 – Tolvaptan Update There is a red statement for tolvaptan on the Mid-Mersey legacy website, published in September 2012 when tolvaptan was funded by CCGs. Funding transferred to NHS England last year, who do not routinely commission the use of tolvaptan, but applications can be made via the NHSE IFR route for exceptional cases. The committee supported the New Medicines Subgroup proposal to signpost to the relevant NHSE information via the APC website and remove the existing red statement from the legacy website.</p> <p>14/41/02 – Dapoxetine The Dapoxetine amber statement and stakeholder feedback were presented. There was a discussion about the RAG status of this drug. The committee was informed that it had been initially sent out for stakeholder consultation as a green statement but was changed to amber based on feedback. This was then sent back out for further stakeholder consultation and consensus feedback supported the amber position. A discussion took place around whether this should be a red drug or even a black drug. Dapoxetine is the only licensed drug for this indication. The motion of whether to keep the drug amber was put to a vote whereupon 11 total including 4 clinicians voted in favour, and 3 total including 1 clinician voted against. As the meeting was not quorate, it was decided that the matter would need to be discussed individually at each CCG organisation.</p> <p>14/41/03 – Rheumatology Business Cases The rheumatology business cases were presented as follows:</p> <ul style="list-style-type: none"> - Biologic agents used sequentially for psoriatic arthritis (PsA), allowing a second biologic if inadequate response to the first (and a third if the second was not tolerated). Existing NICE guidance makes no recommendation in these circumstances. This was approved, along with the accompanying flowchart “Pan-Mersey Biologics Pathway for Psoriatic Arthritis”. - Biologic agents adalimumab and certolizumab used for non-radiographic axial spondyloarthritis (NRAxSpA) where patients had same severity of symptoms to patients with ankylosing spondylitis where NICE recommend use of biologic agents. NICE guidance regarding this is not due until January 2015. This was approved. - Certolizumab as an option for treatment of ankylosing spondylitis (AS) in same circumstances as NICE-approved biologics for this condition, and as an option for PsA and NRAxSpA as above, in each case as an option where other biologic agents are not suitable. This was approved. The Red statements for adalimumab, etanercept, golimumab and infliximab, amended to account for the above business cases, were also approved. <p>14/41/04 – NOAC review A letter has been received from St Helens & Knowsley Hospitals Drug & Therapeutics Committee requesting an early review and update of the APC policy statements for NOACs. There was a clear consensus in favour of this review.</p>	<p>AH</p> <p>PM</p> <p>GR</p> <p>DGG</p>
5	<p>APC/14/42 – Formulary and Guidelines 14/42/01 – Retigabine Prescribing The primary care prescribing of Retigabine has ceased since the report of</p>	

	<p>severe adverse effects in summer 2013, and Walton Neurology Centre have confirmed they have reviewed and discontinued all patients. A suggestion was made to remove it from the formulary but it was agreed no changes would be made as it is still recommended by NICE</p> <p>14/42/02 – Growth hormone (Somatropin) – change in RAG There was a proposal for a change in RAG status for Somatropin from amber to red. EPACT data showed there were only approx.. 18 to 19 patients across the Pan Mersey area and most prescribing is from hospitals. It was highlighted that the proposal was for growth hormone in both adults and children. It was agreed that the drug should be red for children. However there was some expression of interest in making it amber shared care. It was agreed to conduct consultation with stakeholders on whether for adults it should become Red or remain Amber, and if it was to remain Amber whether it should be shared care. It was agreed as part of the consultation that it should include information on likely numbers of patients this would affect. Hospital representatives agreed to supply the CSU with an estimate for the numbers of adults being prescribed somatropin to be included in the consultation. Once consultation has been completed this is to be brought back to the Committee for further consideration.</p> <p>14/42/03 – Dexamfetamine in narcolepsy – change in RAG A proposed change in RAG status for Dexamfetamine from red to amber when used in narcolepsy was presented. The proposal had received mostly positive feedback and was approved by the Committee.</p> <p>14/42/04 – Botulinum toxin type A in chronic anal fissure The botulinum toxin type A red statement and stakeholder feedback were presented. Following proposed minor amendments to the wording in the first paragraph on page 1, the statement was voted upon and approved by the committee.</p> <p>14/42/05 – Generalised Anxiety Disorder guideline This was an update of the previous Mid-Mersey guideline. There were small changes including specifying the role of pregabalin. The guideline was approved by the Committee.</p>	<p>GR</p> <p>GR</p> <p>GR</p> <p>EB</p> <p>NC</p>
6	<p>APC/14/43 – Safety 14/43/01 – Safety update</p> <p>The interface form was discussed. Feedback by the CSU team to reporters within 3 days was requested, if it appeared that further action was required at a locality level.</p> <p>MHRA alert- Domperidone. It was noted that a safety notice providing supporting information for this alert would be circulated by the end of the week.</p>	<p>CM</p>
7	<p>APC/14/44 – Shared Care 14/44/01 – Shared Care update</p> <p>The Committee was updated on the progress of various shared care agreements.</p> <p>The Pan Mersey APC website has been updated to provide information by CCG on approved shared care agreements. It was noted that the South Sefton and Southport and Formby information needed to be checked for accuracy.</p>	<p>CM/HS</p>
9	<p>APC/14/45 – Any Other Business 14/45/01 – AOB</p> <p>The changes with regard to the scheduling of Tramadol placing it in Schedule 3 to the Misuse of Drugs Regulations 2001 and subsequent</p>	<p>All</p>

	changes in practice required were discussed.	
10	<p>APC/14/46 – Date, Time and Venue of the next meeting</p> <p>The next meeting will be held on Wednesday, 25th June 2014 at 1:30 – 3:30pm in The Gallery, The Venue, Civic Way, Poplar Bank, Huyton, L36 9GD</p>	

The agenda and minutes of this meeting may be made available to public and persons outside of The Pan Mersey Area Prescribing Committee Health Community in order to comply with requests made under the Freedom of Information Act 2000.